Preclinical studies have demonstrated that aberrant activation of c-Myc can elicit many of the hallmarks of cancer, while c-Myc inactivation results in sustained tumor regression, a phenomenon that could be attributed to oncogene addiction [13]. This evidence concerns the gene MYC and cancer.